Cargando…
Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials
Digital technology is transforming the development of drugs for Alzheimer's disease and was the topic of the Alzheimer's Association's Research Roundtable on its May 23–24, 2017 meeting. Research indicates that wearable devices and unobtrusive passive sensors that enable the collectio...
Autores principales: | Gold, Michael, Amatniek, Joan, Carrillo, Maria C., Cedarbaum, Jesse M., Hendrix, James A., Miller, Bradley B., Robillard, Julie M., Rice, J. Jeremy, Soares, Holly, Tome, Maria B., Tarnanas, Ioannis, Vargas, Gabriel, Bain, Lisa J., Czaja, Sara J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021547/ https://www.ncbi.nlm.nih.gov/pubmed/29955666 http://dx.doi.org/10.1016/j.trci.2018.04.003 |
Ejemplares similares
-
Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic
por: Sardi, S. Pablo, et al.
Publicado: (2018) -
Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms
por: Lanctôt, Krista L., et al.
Publicado: (2017) -
Making pre-screening for Alzheimer's disease (AD) and Postoperative delirium among post-acute COVID-19 syndrome - (PACS) a national priority: The Deep Neuro Study
por: Tarnanas, Ioannis, et al.
Publicado: (2022) -
Can detection and prediction models for Alzheimer’s Disease be applied to Prodromal Parkinson’s Disease using explainable artificial intelligence? A brief report on Digital Neuro Signatures.
por: Tarnanas, Ioannis, et al.
Publicado: (2022) -
Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time
por: Hendrix, Suzanne B
Publicado: (2012)